Isoindolinone kinase inhibitors

Abstract

Compounds having the formula are useful for inhibiting protein tyrosine kinases. The present invention also discloses methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.

1 . A method for inhibiting a protein kinase in a patient in recognized need of such treatment comprising administering to the patient a therapeutically acceptable amount of a compound of formula (I) 
     
       
         
         
             
             
         
       
     
     or a therapeutically acceptable salt thereof, wherein
 R 1  is selected from the group consisting of hydrogen and alkyl; 
 R 2  is selected from the group consisting of hydrogen, alkoxy, alkoxyalkoxy, alkyl, carboxyalkoxy, carboxyalkyl, halo, haloalkyl, heterocyclylalkoxy, hydroxy, nitro, and —NR c R d ; and 
 one of R 3  and R 4  is A-X-R 5  and the other is hydrogen; wherein A-X-R 5  is drawn with its left end attached to the parent molecular moiety; 
 R 5  is selected from the group consisting of aryl, heteroaryl, and heterocyclyl; 
 A is selected from the group consisting of aryl and heteroaryl, wherein the aryl and the heteroaryl are optionally substituted with one or two substituents independently selected from the group consisting of alkyl, halo, haloalkoxy, and haloalkyl; and 
 X is selected from the group consisting of O, NR a , N(R a )C(S)N(R b ), (CH 2 ) m N(R a )C(O)N(R b )(CH 2 ) n , CH 2 C(O)N(R a ), and N(R a )C(O), wherein R a  and R b  are independently selected from the group consisting of hydrogen and alkyl, m and n are independently 0 or 1, and wherein each group is drawn with its left end attached to A and its right end attached to R 5 . 
 
   
   
       2 . A method for treating cancer in a patient in recognized need of such treatment comprising administering to the patient a therapeutically acceptable amount of a compound of formula (I) 
     
       
         
         
             
             
         
       
     
     or a therapeutically acceptable salt thereof, wherein
 R 1  is selected from the group consisting of hydrogen and alkyl; 
 R 2  is selected from the group consisting of hydrogen, alkoxy, alkoxyalkoxy, alkyl, carboxyalkoxy, carboxyalkyl, halo, haloalkyl, heterocyclylalkoxy, hydroxy, nitro, and —NR c R d ; and 
 one of R 3  and R 4  is A-X-R 5  and the other is hydrogen; wherein A-X-R 5  is drawn with its left end attached to the parent molecular moiety; 
 R 5  is selected from the group consisting of aryl, heteroaryl, and heterocyclyl; 
 A is selected from the group consisting of aryl and heteroaryl, wherein the aryl and the heteroaryl are optionally substituted with one or two substituents independently selected from the group consisting of alkyl, halo, haloalkoxy, and haloalkyl; and 
 X is selected from the group consisting of O, NR a , N(R a )C(S)N(R b ), (CH 2 ) m N(R a )C(O)N(R b )(CH 2 ) n , CH 2 C(O)N(R a ), and N(R a )C(O), wherein R a  and R b  are independently selected from the group consisting of hydrogen and alkyl, m and n are independently 0 or 1, and wherein each group is drawn with its left end attached to A and its right end attached to R 5 .